Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Cat. No. : AAV00125Z
Serotype : AAV Serotype 1 Storage : -80 ℃
Titer: Size:
| Cat. No. | AAV00125Z |
| Description | AAV serotype 1 particles contain Cre recombinase fused to mCherry under the control of CAG promoter. |
| Serotype | AAV Serotype 1 |
| Titer | Varies lot by lot, typically ≥1x10^12 GC/mL |
| Size | Varies lot by lot, for example, 30 μL, 100 μL, 500 μL etc. |
| Storage | Store at -80℃. Avoid multiple freeze/thaw cycles. |
| Shipping | Frozen on dry ice |
| Summary | Creative Biogene ensures high-quality AAV particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between AAV particle lots. |
| Endotoxin | Endotoxins, primarily derived from Gram-negative bacteria, can trigger adverse immune responses. Endotoxin contamination is a significant concern in the production of AAV, especially for applications in animal studies and gene therapy. Effective endotoxin quality control is essential in the development and manufacturing of AAV particles. Creative Biogene utilizes rigorous endotoxin detection methods to monitor the endotoxin level in our produced AAV particles to ensure regulatory compliance. |
| Purity | AAV purity is critical for ensuring the safety and efficacy of AAV-based applications.AAV capsids are composed of three main protein components, known as viral proteins: VP1, VP2, and VP3. These proteins play a critical role in the structure and functionality of the AAV capsid. Monitoring the VP1, VP2, and VP3 content in AAV preparations is essential for quality control in AAV production. Our AAV particles are tested for showing three clear bands of VP1, VP2 VP3 by SDS-PAGE. |
| Sterility | The AAV virus samples are inoculated into the cell culture medium for about 5 days to detect bacterial and fungal growth. |
| Transducibility | Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of AAV to deliver genetic material into target cells or tissues, and assess gene expression and functional activities. |
| Empty vs. Full Capsids | Based-on our proprietary AAV production and purification technology, Creative Biogene can always offer AAV particles with high ratio of full capsids. If required, we can also assess the ratio for a specifc lot of AAV particles by transmission electron microscopy (TEM) or other methods. |
Many intermediate steps in the AAV wild-type infection cycle depend on specific interactions of capsid proteins with infected cells. These steps include initial recognition of surface receptors, induction of endocytosis, release from the endosomal compartment, transport to and entry into the nucleus, and final unpacking of viral DNA from the capsid. These interactions are critical determinants for efficient transduction and expression of target genes when rAAV is used as a gene delivery tool.
Indeed, significant differences in the transduction efficiency of various serotypes into specific tissues and cell types have been described. Therefore, in order to effectively express target genes, it is crucial to select the appropriate serotype. AAV1 is mainly expressed in the liver, followed by the heart and hindlimb skeletal muscles. AAV1 has been studied to treat conditions such as heart disease, alpha-1 antitrypsin deficiency, limb-girdle muscular dystrophy type 2D, Charcot–Marie–tooth neuropathy, and Becker muscular dystrophy.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
We have used the AAV1-CAG-Cre-mCherry across multiple projects, and it consistently delivers outstanding results.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.